Connect with us

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website. .

Business

France’s Sanofi to help Moderna manufacture COVID-19 shots

France's Sanofi to help Moderna manufacture COVID-19 shots

PARIS (Reuters) – Sanofi will fill and pack millions of Moderna COVID-19 vaccines from September in an effort to help meet the demand for the U.S. drugmaker’s shots, the French company said on Monday.

Sanofi said it would help supply up to 200 million doses of Moderna’s vaccine at its Ridgefield facility in New Jersey. Financial details of the arrangement were not disclosed.

The deal marks Sanofi’s third such agreement this year. In January, Sanofi pledged to help supply over 125 million doses of a COVID-19 vaccine made by Pfizer and BioNTech from this summer.

A month later, it said it would fill and finish vials of Johnson & Johnson’s single-shot vaccine at a rate of approximately 12 million doses per month.

Sanofi said it was still working on developing two COVID-19 vaccines, one in partnership with Britain’s GlaxoSmithkline for which it has started new clinical trials after disappointing early-stage results last year, and another with U.S. company Translate Bio.

(Reporting by Matthias Blamont; Editing by Louise Heavens)

Global Banking & Finance Review

 

Why waste money on news and opinions when you can access them for free?

Take advantage of our newsletter subscription and stay informed on the go!

By submitting this form, you are consenting to receive marketing emails from: Global Banking & Finance Review │ Banking │ Finance │ Technology. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Recent Post